within Pharmacolibrary.Drugs.ATC.N;

model N03AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.6666666666666666,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Mephenytoin is an anticonvulsant medication belonging to the hydantoin class, historically used for the treatment of epilepsy and other seizure disorders. Due to the risk of severe adverse effects such as aplastic anemia, it is not commonly used or approved for clinical practice today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals, as no robust published PK parameters were found. Estimates are based on known metabolism (hepatic, CYP2C19), structural similarity to phenytoin, and limited historical reports.</p><h4>References</h4><ol><li><p>Otani, K, et al., &amp; Ishizaki, T (1997). Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. <i>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</i> 16(1) 8–14. DOI:<a href=&quot;https://doi.org/10.1016/S0893-133X(96)00165-0&quot;>10.1016/S0893-133X(96)00165-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8981384/&quot;>https://pubmed.ncbi.nlm.nih.gov/8981384</a></p></li><li><p>Wedlund, PJ, et al., &amp; Wilkinson, GR (1985). Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. <i>The Journal of pharmacology and experimental therapeutics</i> 234(3) 662–669. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4032286/&quot;>https://pubmed.ncbi.nlm.nih.gov/4032286</a></p></li><li><p>Baumann, P, et al., &amp; Nil, R (2021). Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression. <i>Therapeutic drug monitoring</i> 43(3) 436–442. DOI:<a href=&quot;https://doi.org/10.1097/FTD.0000000000000824&quot;>10.1097/FTD.0000000000000824</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33060488/&quot;>https://pubmed.ncbi.nlm.nih.gov/33060488</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AB04;
